Exposure-Safety Analyses Identify Predictors of Change in Bone Mineral Density and Support Elagolix Labeling for Endometriosis-Associated Pain
Abbas Suleiman A, Nader A, Winzenborg I, Beck D, Polepally AR, Ng J, Noertersheuser P, Mostafa NM
Cite this paper
Abbas Suleiman, A., Nader, A., Winzenborg, I., Beck, D., Polepally, A. R., Ng, J., Noertersheuser, P., & Mostafa, N. M. (2020). Exposure-Safety Analyses Identify Predictors of Change in Bone Mineral Density and Support Elagolix Labeling for Endometriosis-Associated Pain. CPT: pharmacometrics & systems pharmacology, 9(11), 639-648. https://doi.org/10.1002/psp4.12560
Abbas Suleiman A, Nader A, Winzenborg I, Beck D, Polepally AR, Ng J, Noertersheuser P, Mostafa NM. Exposure-Safety Analyses Identify Predictors of Change in Bone Mineral Density and Support Elagolix Labeling for Endometriosis-Associated Pain. CPT: pharmacometrics & systems pharmacology. 2020;9(11):639-648. doi:10.1002/psp4.12560
Abbas Suleiman, Ahmed, et al. "Exposure-Safety Analyses Identify Predictors of Change in Bone Mineral Density and Support Elagolix Labeling for Endometriosis-Associated Pain." CPT: pharmacometrics & systems pharmacology, vol. 9, no. 11, 2020, pp. 639-648.
For EndNote, Zotero or Mendeley:
Open access
No open license is recorded for this paper. Reuse terms are set by the publisher.
Open Access
Free full text on PubMed Central (PMC7679073)


